Jo Robson's Outputs (65)

Comment on: Benchmarking tocilizumab use for giant cell arteritis (2022)
Journal Article

It is with great interest we read the editorial on tocilizumab (TCZ) use in giant cell arteritis (GCA) published on 9th May, 2022 by Conway et al [1]. We write to share some of our data to add weight to the views expressed, particularly in relation t... Read More about Comment on: Benchmarking tocilizumab use for giant cell arteritis.

CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study (2022)
Presentation / Conference Contribution

P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness (2022)
Journal Article

Background/Aims
Autoimmune rheumatic conditions are multisystem chronic disorders associated with increased psychological distress. Consequences include poor medication adherence and high levels of disease activity. Psychological interventions may r... Read More about P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness.

P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Presentation / Conference Contribution

Background/Aims
Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.

OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Presentation / Conference Contribution

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis (2022)
Journal Article

Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for granulomatosis with polyangiitis (2022)
Journal Article

Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).
Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases:... Read More about 2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis (2022)
Journal Article

Objective To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).

Methods Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis (2022)
Journal Article

OBJECTIVE: To develop and validate classification criteria for microscopic polyangiitis (MPA). METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identificatio... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for microscopic polyangiitis (2022)
Journal Article

ABSTRACT
Objective: To develop and validate classification criteria for microscopic polyangiitis (MPA).
Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: i) Id... Read More about 2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for microscopic polyangiitis.

Development and validation of a patient reported outcome measure for giant cell arteritis (2021)
Presentation / Conference Contribution

AB0834 Development of a conceptual framework for a patient reported outcome measure to capture patients’ perceptions of glucocorticoid therapy during treatment for rheumatic diseases (2021)
Presentation / Conference Contribution

Background: Glucocorticoids (GCs) are a key treatment for the autoimmune rheumatic diseases; however, they produce numerous physical and psychological side effects.1 The Outcome Measures in Rheumatology (OMERACT) Gl... Read More about AB0834 Development of a conceptual framework for a patient reported outcome measure to capture patients’ perceptions of glucocorticoid therapy during treatment for rheumatic diseases.

Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure (2021)
Journal Article

Objectives: GCA is a large vessel vasculitis (LVV) presenting with headache, jaw claudication, musculoskeletal and visual involvement. Current treatment is glucocorticoids and anti-IL-6 tocilizumab in refractory disease. The objective of this study w... Read More about Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure.

Patient reported outcomes in large vessel vasculitides (2021)
Journal Article

Purpose of Review: The goal of this paper is to review current and future uses of patient-reported outcomes in large vessel vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types of systemic vas... Read More about Patient reported outcomes in large vessel vasculitides.

The patient perspective of nurse-led care in early rheumatoid arthritis: A systematic review of qualitative studies with thematic analysis (2020)
Journal Article

Introduction:
Management of rheumatoid arthritis has changed dramatically over the last decade and is characterised by early start of intensive treatment and tight monitoring of disease activity until remission. The role of nurse-led care at early... Read More about The patient perspective of nurse-led care in early rheumatoid arthritis: A systematic review of qualitative studies with thematic analysis.

SAT0643-HPR Nurse-led care from the perspective of people with early rheumatoid arthritis: A qualitative systematic review (2020)
Journal Article

Background: Nurse-led care has been shown to be clinically effective and cost effective in rheumatoid arthritis (RA) but the role of the nurse in early RA is not well defined. Evidence for processes of care in RA is... Read More about SAT0643-HPR Nurse-led care from the perspective of people with early rheumatoid arthritis: A qualitative systematic review.

Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives (2020)
Journal Article

© The Author(s) 2020. Objectives. CTD and systemic vasculitis impact on health-related quality of life. Treatment can be complex, involving multiple medical specialities. The aim of this study was to investigate psychological and self-management supp... Read More about Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives.

Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis (2020)
Journal Article

Objectives: In treat to target (T2T), the patient is treated to reach and maintain specified and sequentially measured goals, such as remission or low disease activity. T2T in psoriatic arthritis (PsA) has demonstrated improved clinical and patient-r... Read More about Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis.

Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines - Executive summary (2020)
Journal Article

© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) encompasses three disease phenotypes: granul... Read More about Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines - Executive summary.

Treat-to-target in PsA: methods and necessity (2020)
Journal Article

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. With increasing recognition of the high burden and impact of psoriatic arthritis (PsA) and the growing numbe... Read More about Treat-to-target in PsA: methods and necessity.